Recent research has highlighted the potential of GLP-1 agonist drugs, such as Mounjaro, Wegovy, and Ozempic, in reducing inflammation in various organs, including the brain. Scientists are hopeful that these drugs could be used to treat Parkinson’s and Alzheimer’s diseases, as well as alleviate cognitive symptoms associated with depression, bipolar disorder, and mental health disorders. Clinical trials are underway to explore the efficacy of GLP-1 agonists in treating these conditions. The drugs are also being studied for their potential to improve mood and cognitive symptoms.
GLP-1 agonists are all the rage for T2 diabetes, weight loss, and maybe even mental health conditions. Do they have anything to do with mitochondria? Get ready for it... YES, they do! https://t.co/AmwF8XHMS1
The blockbuster medications (GLP-1 agonists) that reduce body weight have another superpower: taming inflammation. Reduced inflammation observed in the liver, kidneys & the brain, raising hopes for treating Parkinson's and Alzheimer's diseases. https://t.co/BEIZkCV2cX
Can Wegovy treat depression as well as obesity? New research looks to GLP-1 drugs for mental illnesses https://t.co/IfD6lZg6bm
Another frontier for GLP-1 drugs like #Ozempic? Scientists are studying if they are helpful in treating depression & bipolar disorder, as well as the decline in cognitive functioning that can come with mental health disorders. @elaineywchen reports. https://t.co/JsX8m01r7q
Researchers are studying whether GLP-1 drugs like Ozempic can help treat depression and bipolar disorder. Early data suggest the drugs can improve mood, as well as cognitive symptoms like impaired memory and focus. My latest: https://t.co/H4ZGSPqsra
The memory and focus problems common to depression, researchers hope, may be alleviated by GLP-1 drugs like Wegovy. "It's a really exciting time," one said. https://t.co/Ux8wMljJBb
Yet another "superpower" of GLP1 agonists is being realized--reducing inflammation throughout the body, including the brain. At least 20 clinical trials are currently testing GLP1 agonists in Parkinson's and Alzheimer's treatment. https://t.co/dbuYdjgDwo
While GLP-1 agonists will undoubtedly be employed to combat metabolic side effects of psych meds (most notably antipsychotics), given their apparent broad anti-inflammatory effects—including in the brain—it will be interesting to see whether they also alleviate the cognitive… https://t.co/vPOA6j8k8G
#GLP1 wt. loss drugs #Mounjaro and #Wegovy — reduce inflammation in the liver, kidneys, heart. & even the brain, leading scientists to hope that the compounds could be used to treat #Parkinson’s and #Alzheimer’s diseases https://t.co/eWBU4tByuf